Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

Radiation Oncology Research

Mission

The mission of the Radiation Oncology Department at the Helen F. Graham Cancer Center is to serve our neighbors and provide state-of-the-art, safe, and high quality radiation therapy care to our cancer patients, while integrating education, clinical translational research, and radiation physics innovations to improve outcomes.

Current Research

  • Institutional Clinical Trials: The Department is involved in institutional outcomes analysis of Head and neck Oropharynx cancer, incidence of HPV+ oropharynx cancer through the multi discipline clinic (MDC) and demographic patterns, outcomes of partial breast brachytherapy, prostate brachytherapy outcomes and prostate IMRT outcomes.
  • National Cancer Institute Clinical Trials: The department is participating in several clinical trials, bringing innovations and new approaches to cancer patients. We are active in national cooperative groups, including the Radiation Therapy Oncology Group (RTOG), Gynecologic Oncology Group (GOC), NRG. Several members of the department are involved in NCI and COG trial evaluation and steering committees to evaluate new trials.
  • Radiation Physics Research: Clinical physics research programs include advanced dose calculation algorithms, adaptive planning, Atlas-based target delineation, and image-guided radiotherapy.
  • Workflow Enhancement & Safety: Using tools of Lean Six Sigma, we are making our department more efficient and also reducing errors. We are evaluating the role of Dashboards in process improvement and ability to do analysis of outcomes of various treatment strategies and cost.
  • Residency Programs: Accredited radiation oncology and medical physics residency programs have been established since 2013.
  • Translational Research: Ongoing collaborations with the Center for Translational Cancer Research and the Wistar Institute, such as radiobiological modeling of the interactions of immune checkpoint inhibitors and abscopal effect for IMRT and HDR brachytherapy.

Members

Firas Mourtada, MSE, Ph.D., D.ABR, Chief of Clinical Physics.
Adam Raben, M.D., Chair, Radiation Oncology.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.